Tari A. King, MD, FSSO, on the Past Year in Breast Cancer Research

Video

The breast cancer expert discussed the latest developments in breast cancer research and what she hopes the next year will offer this patient population.

With breast cancer being the most common cancer among women in the US outside of skin cancers, it is as important as ever for research to continue to advance treatments for this patient population.

According to the American Cancer Society, an estimated 276,480 new cases of invasive breast cancer were diagnosed in women in 2020 and an estimated 48,530 new cases of carcinoma in situ were diagnosed. Moreover, the organization estimated that approximately 42,170 women would die from breast cancer.

In an interview with CancerNetwork®, Tari A. King, MD, FSSO, associate chair for Multidisciplinary Oncology in the Department of Surgery and chief of the Division of Breast Surgery at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, as well as Anne E. Dyson Professor of Surgery in the Field of Women’s Cancers at Harvard Medical School, spoke about the latest developments in breast cancer research and what she hopes 2021 will bring for this patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

American Cancer Society. How Common Is Breast Cancer? American Cancer Society website. Published January 8, 2020. Accessed December 21, 2020. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html

Recent Videos
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Related Content